BRCA1 and ovarian cancer: Platinum and PARP inhibitor sensitivity commonly coexist in BRCA1/2-mutated ovarian cancer due to homologous recombination deficiency (HRD) [291]; however, nucleotide excision repair (NER) alterations confer enhanced platinum sensitivity but not PARP inhibitor sensitivity [292].